Clinical Core

项目总结-临床核心（核心B） 威斯康星州阿尔茨海默病研究中心（ADRC）临床核心的主要目标是 为研究者提供了接触特征良好、多样化的患者和对照人群的机会， 标准化的临床、认知、脑脊液（CSF）、血清/血浆、DNA和神经影像学数据， 促进阿尔茨海默病（AD）临床前诊断和早期干预的转化研究。与 最后，核心对轻度认知障碍（MCI）患者进行全面的临床评估， AD导致的轻度痴呆、认知正常的老年对照（OCN，>65岁）和中年人（IMPACT 队列，45-65岁），基于家族史具有不同程度的痴呆风险。临床核心团队工作 与所有核心密切合作，通过参与外展和招募活动来促进中心的使命， 不同的社区;对核心参与者进行标准化的临床和认知评估;收集 辅助的与衰老相关的认知和临床数据，包括详细的血管风险评估;收集高- 高质量血液、CSF和DNA生物标本;协调生物标本采集与神经影像学检查;完成 及时进行标准化数据报告;进行皮肤活检以获得诱导多能 干细胞（iPSC）系;同意进行脑尸检的核心参与者;促进认知测试和CSF 在申办者发起的研究中收集;并确保及时提供参与者、数据和 生物标本提供给当地和其他地方的研究人员。在下一个赠款周期，核心基金将完成以下工作： 目标：目标1：继续招募和保留认知未受损的成年人（IMPACT和OCN）和患者 与MCI进行详细的年度（MCI，OCN）或两年期（IMPACT）临床评估（包括标准化 统一数据集[UDS]数据和血液样本）以及两年期（MRI、CSF）和基线（PET子集） 生物标志物评估，以支持临床前痴呆症的转化研究。目标2：继续招募和 保留AD所致轻度痴呆患者进行详细的年度临床和血液生物标志物评估 （包括标准化UDS数据）和可选的额外基线生物标志物评估（MRI、CSF、PET）。 目标3：继续整合文化定制的外展，教育和临床服务， 社区提高对大脑健康的认识，并鼓励长期的研究参与（包括 临床和生物标志物评估）和在代表性不足的少数群体社区的宣传。目标4：继续 获得大脑捐赠的同意，以支持临床病理研究，并收集CSF，血液，DNA， iPSCs用于MCI和AD痴呆临床前标志物的转化研究。目标5：继续提供 基础设施，资源和服务，以促进正常认知老化，临床前 老年痴呆症和AD引起的痴呆症，并加快与国家阿尔茨海默氏症 协调中心，国家阿尔茨海默病细胞库，和其他AD中心和研究人员。

PROJECT SUMMARY - CLINICAL CORE (CORE B) The primary objective of the Wisconsin Alzheimer's Disease Research Center's (ADRC) Clinical Core is to provide investigators access to well-characterized, diverse patient and control populations and high-quality, standardized clinical, cognitive, cerebrospinal fluid (CSF), serum/plasma, DNA, and neuroimaging data to facilitate translational Alzheimer's disease (AD) research in preclinical diagnosis and early intervention. To that end, the Core conducts comprehensive clinical evaluations in patients with mild cognitive impairment (MCI) and mild dementia due to AD, cognitively normal older controls (OCN, >65 years), and middle-aged adults (IMPACT cohort, 45-65 years) with varying levels of dementia risk based on family history. The Clinical Core team works closely with all Cores to facilitate the Center's mission by participating in outreach and recruitment activities to diverse communities; conducting standardized clinical and cognitive assessments of Core participants; gathering ancillary aging-related cognitive and clinical data, including a detailed vascular risk assessment; collecting high- quality blood, CSF, and DNA biospecimens; coordinating biospecimen collection with neuroimaging; completing standardized data reporting in a timely manner; conducting skin biopsies for acquisition of induced pluripotent stem cell (iPSC) lines; consenting Core participants for brain autopsy; facilitating cognitive testing and CSF collection within investigator-initiated studies; and ensuring timely availability of participants, data, and biospecimens to researchers locally and beyond. In the next grant cycle, the Core will accomplish the following aims: Aim 1: Continue to recruit and retain cognitively unimpaired adults (IMPACT and OCN) and patients with MCI for detailed annual (MCI, OCN) or biennial (IMPACT) clinical assessments (including standardized Uniform Data Set [UDS] data and blood samples) and for biennial (MRI, CSF) and baseline (PET in subset) biomarker assessments to support translational research in preclinical dementia. Aim 2: Continue to recruit and retain patients with mild dementia due to AD for detailed annual clinical and blood biomarker assessments (including standardized UDS data) and optional additional baseline biomarker assessments (MRI, CSF, PET). Aim 3: Continue to integrate culturally-tailored outreach, education, and clinical services to diverse communities to raise awareness of brain health and encourage long-term research engagement (including clinical and biomarker assessments) and advocacy in underrepresented minority communities. Aim 4: Continue to obtain consents for brain donation to support clinical-pathologic research and collect CSF, blood, DNA, and iPSCs for translational research on preclinical markers of MCI and AD dementia. Aim 5: Continue to provide infrastructure, resources, and services to facilitate collaborative research in normal cognitive aging, preclinical dementia, and dementia due to AD and expedite sharing of data and resources with the National Alzheimer's Coordinating Center, National Cell Repository for Alzheimer's Disease, and other AD Centers and investigators.